As part of the reinforced surveillance of vaccines used against Covid-19, a pharmacovigilance survey is set up to monitor in real time the safety profile of vaccines available in France based on declarations made by health professionals, vaccinated people or their entourage. The results of this evaluation and monitoring were shared with the members of the ANSM monitoring committee with the French CRPV network on April 13, 2023, in order to identify potential signals and consider the measures to be taken.

Comirnaty vaccine (BioNTech-Pfizer)

The analysis of adverse reactions reported with the Comirnaty vaccine covers data validated from 03/10/2023 to 04/6/2023.

Since the start of vaccination, 126,172 cases of adverse effects have been reported. The majority of adverse effects are expected and not serious. In total, more than 123,410,500 injections have been carried out as of April 6, 2023.

There were no new signals identified over the period with the Comirnaty vaccine.

Spikevax vaccine (Moderna)

The analysis of adverse reactions reported with the Spikevax vaccine covers data validated from 03/10/2023 to 04/6/2023.

Since the start of vaccination with the Spikevax vaccine (Moderna), 33,625 cases of adverse reactions have been reported. The majority of adverse effects are expected and not serious. In total, more than 24,200,900 injections have been carried out as of April 6, 2023. Since November 8, 2021, the use of the Spikevax vaccine has been reserved for people aged 30 and over.

There were no new signals identified over the period with the Spikevax vaccine.

Nuvaxovid vaccine (Novavax)

The analysis of adverse reactions reported with the Nuvaxovid vaccine covers data validated from 03/10/2023 to 04/6/2023.

Since the start of vaccination with the Nuvaxovid vaccine (Novavax), 98 cases of adverse reactions have been reported. The majority of adverse effects are expected and not serious. In total, more than 40,300 injections have been carried out as of April 6, 2023.

There were no new signals identified with the Nuvaxovid vaccine.

Vidprevtyn vaccine (Sanofi)

The analysis of adverse reactions reported with the Vidprevtyn vaccine covers data validated from 03/10/2023 to 04/6/2023.

Vaccination with the Vidprevtyn vaccine began in France on December 19, 2022. In total, more than 6,500 injections were carried out as of April 6, 2023. To date, 2 non-serious adverse reactions have been reported.

There was no signal identified with the Vidprevtyn vaccine.